This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Immunogène
This Ketohexokinase (KHK) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 251-281 amino acids from the C-terminal region of human Ketohexokinase (KHK).
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C,-20 °C
Stockage commentaire
Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Date de péremption
6 months
Springer, Lindbloom-Hawley, Schermerhorn: "Tissue expression of ketohexokinase in cats." dans: Research in veterinary science, Vol. 87, Issue 1, pp. 115-7, (2009) (PubMed).
Diggle, Shires, Leitch, Brooke, Carr, Markham, Hayward, Asipu, Bonthron: "Ketohexokinase: expression and localization of the principal fructose-metabolizing enzyme." dans: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, Vol. 57, Issue 8, pp. 763-74, (2009) (PubMed).
Ketohexokinase (KHK), or fructokinase, catalyzes conversion of fructose to fructose-1-phosphate. Splice variant 1 is the highly active form found in liver, renal cortex, and small intestine, while splice variant 2 is the lower activity form found in most other tissues. KHK, like glucokinase (GCK) and glucokinase regulator (GCKR), is present in both liver and pancreatic islets. The inhibition of GCK by GCKR is blocked by binding of fructose-1-phosphate to GCKR. The chromosomal proximity of the metabolically connected GCKR and KHK genes has a genetic linkage in type 2 diabetes. Fructosuria, or hepatic fructokinase deficiency, is a benign, asymptomatic defect of intermediary metabolism associated with heterozygosity for G50R and A43T mutations in KHK.